New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

Pakistan’s healthcare landscape has entered a pivotal phase in the management of diabetes and obesity. For years, advanced ...

Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have ...

GLP-1 RA use was associated with improved cardiometabolic outcomes among pediatric patients with type 2 diabetes and obesity.

Academics from Emory University in Atlanta have found that GLP-1 RAs significantly protect people with type 2 diabetes and ...

Glucagon-like peptide 1 receptor agonists (GLP-1RA) have made waves as treatments for obesity and type 2 diabetes, but a new report suggests they might also have clinical benefits for certain patients ...

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

About BMF-650 BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity. Related to the broader orforglipron chemotype, ...

An Italian study shows that using GLP-1 receptor agonists can lead to remission in up to 18% of cases, especially when used ...

40% of GLP-1RA prescriptions were unfilled due to high costs, insurance barriers, and potential racial biases, affecting access for minority groups. Uninsured patients faced significant financial ...